Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
Ardmore Shipping(US:ASC) Prnewswire·2025-09-22 00:10临床试验结果 - ASC47与司美格鲁肽联合用药的胃肠道耐受性显著优于司美格鲁肽单药治疗 [1] - ASC47联合用药组的呕吐发生率为6.7%，远低于司美格鲁肽单药治疗组的57.1% [1]